Related Experiment Video

Updated: Nov 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung

Keigo Kobayashi1, Hideki Terai2, Hiroyuki Yasuda1

  • 1Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Biochemical and Biophysical Research Communications
|December 10, 2020
PubMed

Insights

New cell models reveal KRAS-mutant lung cancer's specific features, focusing on the IGF2-IGF1R pathway. This research aids in developing targeted therapies and overcoming resistance to KRAS G12C inhibitors like AMG 510.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Molecular targeted therapy has advanced lung cancer treatment, but KRAS-mutant lung cancer lacks specific therapies.
  • KRAS mutations are common in lung cancer, yet targeted treatments remain limited.
  • Understanding KRAS-mutant lung cancer biology is crucial for developing effective treatments.

Purpose of the Study:

  • To characterize molecular and pathological features of KRAS-mutant lung cancer using novel cell line models.
  • To investigate the role of the IGF2-IGF1R pathway in KRAS-mutant lung cancer.
  • To provide a tool for developing clinical treatment strategies and understanding drug resistance.

Main Methods:

  • Development and utilization of novel cell line models for KRAS-mutant lung cancer.
  • Characterization of specific molecular and pathological features.
  • Focus on the Insulin-like Growth Factor 2 (IGF2) - Insulin-like Growth Factor 1 Receptor (IGF1R) pathway.

Main Results:

  • Successfully characterized specific molecular and pathological features of KRAS-mutant lung cancer.
  • Identified the IGF2-IGF1R pathway as a key feature in KRAS-mutant lung cancer.
  • The developed cell line model elucidates differences in driver oncogenes.

Conclusions:

  • The developed cell line model is a valuable tool for understanding KRAS-mutant lung cancer biology.
  • This research provides insights into drug resistance mechanisms, particularly for AMG 510.
  • The findings may facilitate the development of new targeted therapies for KRAS-mutated lung cancer.
Keywords:
AMG510IGF1RKRAS G12CLung cancer

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.4K
Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing11:00

Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing

Published on: November 29, 2018

14.7K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.7K